The fixed ratio is RELEVANT for identifying COPD Source: Annual Congress 2008 - Defining COPD using the "fixed ratio" (FEV1/FVC <0.70) – pro and con Year: 2008
The fixed ratio is NOT RELEVANT for identifying COPD Source: Annual Congress 2008 - Defining COPD using the "fixed ratio" (FEV1/FVC <0.70) – pro and con Year: 2008
GOLD stage 0 and risk of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 352s Year: 2003
FEV1/FEV3 ratio as an alternative to fixed ratio of FEV1/FVC Source: International Congress 2018 – Biomarkers and lung function in airway disease Year: 2018
Hyperinflation in GOLD 2 COPD Source: Eur Respir J 2006; 28: Suppl. 50, 806s Year: 2006
Excess lung function decline is associated with GOLD stage 0 Source: Annual Congress 2009 - Methodological aspects of asthma and COPD epidemiology Year: 2009
GOLD 2011 versus GOLD 2017 – What does change? Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers Year: 2017
The ABCD of GOLD made clear Source: Eur Respir J 2013; 42: 1163-1165 Year: 2013
COPD GOLD stage 1: Is it really a disease? Source: Annual Congress 2011 - COPD mechanisms Year: 2011
Validation of non-spirometric predictors of COPD to the GOLD stage classification Source: Eur Respir J 2002; 20: Suppl. 38, 123s Year: 2002
Stage 0 in GOLD does not predict future clinical COPD Source: Eur Respir J 2002; 20: Suppl. 38, 401s Year: 2002
The distribution of COPD in general practice using three different GOLD classification Source: International Congress 2018 – COPD around the world Year: 2018
Fixed ratio or LLN for defining airflow obstruction in population screening Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers Year: 2017
The prevalence of QTc-prolongation increase by GOLD stage in COPD Source: International Congress 2017 – Prevalence, prognosis and comorbidities of COPD and factors associated with lung function Year: 2017
Impact of comorbidities on survival of patients with COPD according to GOLD stages Source: Annual Congress 2011 - COPD: burden of disease, imaging and management Year: 2011
Distribution of a COPD population based on the GOLD assessment framework Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease Year: 2012
Total mortality risks in relation to the GOLD stages in a long term follow-up - a special analysis of GOLD stage 0 Source: Annual Congress 2004 - Burden of obstructive lung diseases: costs, mortality and life impairment Year: 2004
Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1 Source: Eur Respir J 2004; 23: 497-498 Year: 2004
GOLD 2017 versus GOLD 2011 - comparison of the risk of exacerbations and mortality in COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018
COPD in smokers: extension of emphysema, assessed by helical CT, and GOLD stages Source: Eur Respir J 2004; 24: Suppl. 48, 67s Year: 2004